ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Early Haemodynamic Performance and Clinical Outcomes of a Novel Bioprosthetic Mitral Valve.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe MITRIS RESILIA mitral bioprosthesis is a novel pericardial valve developed to improve durability and haemodynamic performance. However, clinical data on its use in mitral valve replacement are limited. This single-center retrospective study aimed to evaluate the early haemodynamic performance and clinical outcomes of the MITRIS RESILIA valve in patients requiring mitral valve replacement.
methodsWe retrospectively reviewed data from 66 patients who underwent mitral valve replacement using MITRIS RESILIA between May 2021 and May 2024. Transthoracic echocardiography was used to assess valve haemodynamic performance at discharge, 1 year, and 2 years postoperatively. The primary end-point was early valve haemodynamics, and the secondary end-points were overall survival and structural valve deterioration.
resultsThe mean age of the cohort was 75.0 ± 5.8 years, and 48.5% of the patients were male. The mean pressure gradient was 3.9 ± 1.4 mmHg at discharge, 4.0 ± 2.0 mmHg at 1 year, and 3.9 ± 1.3 mmHg at 2 years. The effective orifice area was 1.52 ± 0.50 cm2 after surgery. None of the patients experienced structural valve deterioration or significant paravalvular leak. The rate of freedom from all-cause mortality at 2 years was 93.3%.
conclusionsMITRIS RESILIA demonstrated stable early haemodynamic performance across all valve sizes, including the 23 mm prosthesis. No cases of structural valve deterioration or paravalvular leak were observed, supporting its feasibility for mitral valve replacement. Further studies with extended follow-up are required to confirm the long-term durability and clinical benefits of the valve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.